A number of research firms have changed their ratings and price targets for Allergan PLC. (NYSE: AGN):

  • 10/2/2017 – Allergan PLC. had its “equal weight” rating reaffirmed by analysts at Barclays PLC.
  • 10/2/2017 – Allergan PLC. had its “buy” rating reaffirmed by analysts at Wells Fargo & Company.
  • 9/26/2017 – Allergan PLC. had its “outperform” rating reaffirmed by analysts at Credit Suisse Group. They now have a $266.00 price target on the stock, down previously from $286.00.
  • 9/26/2017 – Allergan PLC. had its “buy” rating reaffirmed by analysts at UBS AG. They now have a $275.00 price target on the stock.
  • 9/25/2017 – Allergan PLC. had its price target lowered by analysts at Royal Bank Of Canada from $285.00 to $277.00. They now have an “outperform” rating on the stock.
  • 9/25/2017 – Allergan PLC. had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $267.00 price target on the stock.
  • 9/23/2017 – Allergan PLC. had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $400.00 price target on the stock.
  • 9/22/2017 – Allergan PLC. had its “hold” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $231.00 price target on the stock. They wrote, “Allergan announced mixed top-line results from its Phase 2b study of CVC for NASH. The Street was waiting for this, and the delay relative to Street expectations had been one reason the stock has been weak.””
  • 9/20/2017 – Allergan PLC. was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating. They now have a $228.00 price target on the stock, down previously from $284.00.
  • 9/20/2017 – Allergan PLC. had its “buy” rating reaffirmed by analysts at Citigroup Inc.. They now have a $280.00 price target on the stock.
  • 9/12/2017 – Allergan PLC. had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $262.00 price target on the stock.
  • 9/11/2017 – Allergan PLC. had its “outperform” rating reaffirmed by analysts at Wells Fargo & Company.
  • 9/6/2017 – Allergan PLC. had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $285.00 price target on the stock.
  • 8/29/2017 – Allergan PLC. had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $400.00 price target on the stock.
  • 8/29/2017 – Allergan PLC. had its “hold” rating reaffirmed by analysts at Cantor Fitzgerald.
  • 8/25/2017 – Allergan PLC. was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 8/22/2017 – Allergan PLC. had its “hold” rating reaffirmed by analysts at Cantor Fitzgerald. They wrote, “We believe that NASH (non-alcoholic steatohepatitis) represents a large unmet need and that the market opportunity for new drugs could total $8-10B.””
  • 8/17/2017 – Allergan PLC. was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 8/14/2017 – Allergan PLC. had its “buy” rating reaffirmed by analysts at Argus. They now have a $280.00 price target on the stock.
  • 8/9/2017 – Allergan PLC. had its “outperform” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $280.00 price target on the stock, up previously from $270.00.
  • 8/9/2017 – Allergan PLC. was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 8/9/2017 – Allergan PLC. had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $278.00 price target on the stock, up previously from $273.00.
  • 8/9/2017 – Allergan PLC. had its “outperform” rating reaffirmed by analysts at UBS AG. They now have a $275.00 price target on the stock.
  • 8/5/2017 – Allergan PLC. was given a new $288.00 price target on by analysts at Credit Suisse Group. They now have a “buy” rating on the stock.

Shares of Allergan PLC. (NYSE AGN) opened at 209.80 on Wednesday. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80. The firm has a 50-day moving average price of $220.20 and a 200-day moving average price of $233.72. The firm has a market capitalization of $70.14 billion, a P/E ratio of 6.39 and a beta of 1.15.

Allergan PLC. (NYSE:AGN) last announced its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. During the same period in the previous year, the firm posted $3.35 earnings per share. The company’s revenue was up 8.8% on a year-over-year basis. On average, equities research analysts anticipate that Allergan PLC. will post $16.22 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Friday, August 18th were paid a dividend of $0.70 per share. The ex-dividend date was Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.33%. Allergan PLC.’s dividend payout ratio (DPR) is currently 9.95%.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.